|
Mitomycin-C Clinical Trials
8 actively recruiting trials across 5 locations
▲ +1 trial since June 2026
Also known as: HIPEC, Sequential treatment group, • MMC
Pipeline
Phase 1: 1Phase 2: 2Phase 3: 3Phase 4: 1
Top Sponsors
- University of Southampton1
- Sarcoma Oncology Research Center, LLC1
- National Cancer Institute (NCI)1
- National Cancer Center, Korea1
- Janssen Research & Development, LLC1
Indications
- Cancer8
- Atypical Mesothelial Proliferation1
- Non-Muscle Invasive Bladder Neoplasms1
- Peritoneal Mesothelioma1
- Urinary Bladder Neoplasms1
Other3 trials
Sun City, Arizona1 trial
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Academic Urology and Urogynecology of Arizona
Phase 3
Santa Barbara, California1 trial
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Samsun Clinic - Ridley-Tree Cancer Center
Phase 3
Santa Monica, California1 trial
Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors
Sarcoma Oncology Research Center / Cancer Center of Southern California
Phase 2
Bethesda, Maryland1 trial
New York, New York1 trial
Adaptive Radiation in Anal Cancer
Columbia University Irving Medical Center
N/A
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.